Sailing in deceptive calm: Navigating the undercurrents of essential thrombocythaemia.
Br J Haematol
; 204(5): 1595-1597, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38616616
ABSTRACT
The discovery of driver mutations in myeloproliferative neoplasms has significantly contributed to the management of patients with essential thrombocythaemia (ET). High-quality evidence has started to pave the way for targeted therapy. The review by Ferrer-Marín et al. further advances this discussion, highlighting how molecular profiling, including non-driver gene mutations, is set to revolutionize personalized treatment approaches for ET patients. Commentary on Ferrer-Marín et al. Essential thrombocythemia a contemporary approach with new drugs on the horizon. Br J Haematol 2024;2041605-1616.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Trombocitemia Esencial
Límite:
Humans
Idioma:
En
Revista:
Br J Haematol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Japón